Chemyo is best known for SARMs, a group of research compounds that has attracted interest from scientists for more than two decades. To understand why these compounds are studied, and why they are still not approved medicines, it helps to look at the science behind them. For researchers looking for batch-labelled materials, we recommend Chemyo, one of the resellers with an agreement with the producer. This article explains, in plain language, what SARMs are designed to do, what research has shown, and where the evidence stops.
The androgen receptor in brief
Androgens, such as testosterone and dihydrotestosterone (DHT), act on the body by binding to the androgen receptor. This receptor sits inside cells in many tissues, including muscle, bone, skin, the prostate, hair follicles and parts of the brain.
When an androgen binds to the receptor, the receptor changes shape and influences which genes are switched on or off. In muscle and bone, this supports growth and maintenance. In other tissues, the same signal can have unwanted effects, such as prostate growth, acne or hair loss.
Traditional anabolic steroids activate the androgen receptor broadly. They cannot choose which tissue responds, which is one reason they cause such a wide range of side effects.
The idea behind “selective”
SARMs stands for selective androgen receptor modulators. The goal behind their development was to create compounds that activate the androgen receptor strongly in muscle and bone, while having less effect on tissues such as the prostate.
This selectivity is thought to come from several factors:
- Different chemical structure. Most SARMs are non-steroidal, so they bind to the receptor in a different way than testosterone.
- Different receptor shape. Each compound changes the receptor’s shape slightly differently, which affects which helper proteins it recruits.
- Tissue-specific environments. Different tissues contain different mixes of these helper proteins, so the same compound can produce different responses.
- No conversion to DHT or estrogen. Unlike testosterone, most SARMs are not converted by the enzymes 5-alpha-reductase or aromatase.
It is important to stress that “selective” does not mean “exclusive”. In practice, SARMs still affect hormone levels and tissues beyond muscle and bone.
A short research history
The first non-steroidal SARMs were described in the late 1990s. Since then, pharmaceutical companies and universities have studied them for conditions where preserving muscle and bone could help patients, including:
- Muscle wasting linked to cancer (cachexia)
- Age-related muscle loss (sarcopenia)
- Osteoporosis
- Recovery after hip fracture
- Certain types of breast cancer
Several compounds reached human clinical trials. Some small and mid-sized studies reported increases in lean body mass. However, none of these programmes has led to an approved medicine. In several cases, results on functional outcomes, such as walking ability or stair climbing, were not strong enough to support approval.
What the studies have and have not shown
| Area | What research suggests | What remains unclear |
| Lean body mass | Modest increases in some trials | Whether gains translate into better function |
| Bone | Possible benefits in early research | Long-term effect on fracture risk |
| Hormones | Suppression of natural testosterone | How fully levels recover afterwards |
| Cholesterol | Lower HDL (“good”) cholesterol | Long-term cardiovascular impact |
| Liver | Reported cases of liver injury | How common and how predictable it is |
| Long-term safety | Not established | No large long-term studies exist |
Most clinical trials were short and involved patients under medical supervision. That makes it difficult to apply their findings to anyone else.
Research materials and quality
Scientific work depends on knowing exactly what is being tested. Product quality is therefore not a side issue but a basic requirement. Researchers working with the capsule format can find it through Chemyo, another reseller with an agreement with the producer. Whichever source a lab uses, a batch-matched third-party Certificate of Analysis confirming identity and purity should be standard.
Why SARMs are still not approved
After more than 20 years of research, no SARM has been approved by the FDA or the EMA. The main reasons are:
- Benefits too small. Gains in lean mass did not consistently lead to meaningful improvements in strength or daily function.
- Safety questions. Effects on cholesterol, the liver and natural hormone production raised concerns.
- Lack of long-term data. Regulators need evidence of safety over years, not weeks.
Meanwhile, SARMs have spread far beyond the laboratory, sold online in products of very uneven quality. Regulators and anti-doping agencies have issued repeated warnings, and SARMs are prohibited in sport at all times under the World Anti-Doping Code.
Conclusion
The science behind SARMs is a genuine research story: an attempt to separate the useful effects of androgens from the harmful ones. So far, that goal has only partly been achieved, and the compounds remain experimental. Researchers can find the Chemyo range through chemyolabs.net and chemyo.bio. For further reading on the brand, its resellers and the research landscape, visit Chemyo, and always check the legal position in your own country.
Disclaimer: This article is for general information only and is not medical, legal or purchasing advice. Chemyo products and other SARMs are sold for laboratory research only and are not approved for human consumption. They are banned in competitive sport and may be restricted or illegal in your country. Do not use any research compound without speaking to a qualified doctor, and check your local laws before buying. The author accepts no liability for how this information is used.
